MRO has acquired Clinetic for an undisclosed amount. This corporate transaction integrates Clinetic’s health software and technology capabilities into MRO’s operations, signaling a strategic enhancement of its offerings in the health information and clinical trial sectors. The acquisition is focused on leveraging real-world data for research, evidence generation, and new care delivery models.
Clinetic is a health software and technology company dedicated to unleashing the potential of electronic health record systems for clinical research. Its enterprise software solution directly addresses significant challenges in patient recruitment, such as complex protocols, resource-strained research sites, and persistent enrollment shortfalls that contribute to costly study delays. Clinetic's platform utilizes AI-powered clinical curation and real-time patient matching to efficiently identify and enroll patients from its network of over 20 million patients.
This acquisition is strategic for MRO, as it gains Clinetic's innovative technology and established network within health systems. Clinetic's specialized ability to transform medical record data into actionable insights for patient recruitment directly aligns with MRO's objectives to improve efficiency in health information management and clinical trial processes. The expected synergies include an accelerated ability to identify and enroll eligible patients for clinical studies, which can significantly reduce the timelines and costs associated with research efforts.
By combining MRO’s existing capabilities with Clinetic’s advanced software, the unified entity is positioned to advance smarter, faster clinical trial recruitment. This integration is anticipated to accelerate drug development, enhance research efficiency for both pharmaceutical companies and health systems, and facilitate the more rapid introduction of new therapies and care models to patients. The combined organization aims to solidify its position as a leader in leveraging real-world data to power clinical research and innovation.